3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
申请人:Dunn Robert
公开号:US20090069337A1
公开(公告)日:2009-03-12
The present disclosure provides compounds having affinity for the 5-HT
6
receptor which are of the formula (I):
wherein Q, R
1
, R
4
, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
[EN] 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY<br/>[FR] COMPOSÉS SUBSTITUÉS EN POSITION 3' AYANT UNE AFFINITÉ VIS-À-VIS DU RÉCEPTEUR 5-HT6
申请人:MEMORY PHARM CORP
公开号:WO2009023844A2
公开(公告)日:2009-02-19
The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
NOVEL BENZIMIDAZOLE DERIVATIVE
申请人:Carna Biosciences, Inc.
公开号:EP4129406A1
公开(公告)日:2023-02-08
A benzimidazole derivative represented by formula (I) (wherein A1 to A3 and R1 to R6 are as described in the description) or a pharmaceutically acceptable salt thereof, which inhibits activation of STING pathway and, therefore, which is useful as a prophylactic or therapeutic medicine for inflammatory diseases, autoimmune diseases, cancer, etc.